Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving beyond anatomy: the future of rectal cancer management is biologically-informed, response-adapted, and patient-centered.

Clinical and translational radiation oncology·2026
Same author

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.

Cancer cell·2026
Same author

Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.

Cell·2026
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

IRF4: Immunity. Malignancy! Therapy?

Arthur L Shaffer1, N C Tolga Emre, Paul B Romesser

  • 1Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 23, 2009
PubMed
Summary
This summary is machine-generated.

Interferon Regulatory Factor 4 (IRF4) is crucial for immune cell development and is essential for multiple myeloma cancer cells. Targeting IRF4 offers a promising therapeutic strategy for this plasma cell malignancy.

More Related Videos

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
08:57

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

Related Experiment Videos

Last Updated: Jun 23, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
08:57

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Interferon Regulatory Factor 4 (IRF4) is a transcription factor vital for immune cell differentiation.
  • IRF4 plays a critical role in the development of B cells into antibody-secreting plasma cells.
  • Aberrant IRF4 expression is linked to various lymphoid malignancies.

Purpose of the Study:

  • To investigate the role of IRF4 in multiple myeloma pathogenesis.
  • To explore the therapeutic potential of targeting IRF4 in plasma cell malignancies.

Main Methods:

  • Analysis of IRF4 expression in immune cells and multiple myeloma.
  • Investigating the functional impact of IRF4 interference on multiple myeloma cells.

Main Results:

  • IRF4 is essential for multiple myeloma cell survival, regardless of genetic background.
  • Interfering with IRF4 expression demonstrates lethal effects on multiple myeloma cells.

Conclusions:

  • IRF4 is a critical regulator in multiple myeloma and represents a key therapeutic target.
  • Targeting IRF4 presents a potential "Achilles' heel" strategy for treating multiple myeloma.